SEC Form 4 · accession 0001209191-15-039638
Viking Therapeutics, Inc. · VKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian Lian
Officer — President & CEO · Director
Period of report
May 4, 2015
Accepted (ET)
May 6, 2015 · 8:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001607678
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.00001 per shareF1,F2,F3 | May 4, 2015 | D | 2,313,406 | — | D | 1,336,594 | D | |
| Common Stock, par value $0.00001 per share | May 4, 2015 | A | 87,500 | $0.00 | A | 1,424,094 | D | |
| Common Stock, par value $0.00001 per shareF5 | May 4, 2015 | C | 2,731 | — | A | 1,426,825 | D | |
| Common Stock, par value $0.00001 per shareF5 | May 4, 2015 | C | 9,927 | — | A | 1,436,752 | D | |
| Common Stock, par value $0.00001 per share | May 4, 2015 | F | 16,346 | $9.49 | A | 1,453,098 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F7 | $9.49 | May 4, 2015 | A | 87,500 | A | May 4, 2015 | May 4, 2025 | Common Stock | 87,500 | 87,500 | D |
| Convertible Note due 2015F5 | $6.00 | May 4, 2015 | C | — | D | — | — | Common Stock | 2,731 | 0 | D |
| Convertible Note due 2015F5 | $6.00 | May 4, 2015 | C | — | D | — | — | Common Stock | 9,927 | 0 | D |
Explanation of responses
- F1Of the shares repurchased by the Issuer, 1,516,308 shares were fully vested and 797,098 were subject to vesting.
- F2Shares were repurchased by the Issuer at a price of $0.00001 per share.
- F3Includes 460,534 shares of restricted stock that are subject to vesting, of which: (a) 18,869 shares will vest on May 26, 2015 and each month thereafter through and including August 26, 2015, (b) 18,868 shares will vest on September 26, 2015, (c) 183,095 will vest upon the achievement of a company milestone, and (d) 183,095 will vest upon the achievement of an additional company milestone.
- F4Represents a restricted stock award of common stock under the Issuer's 2014 Equity Incentive Plan. One third of the shares subject to the restricted stock award shall vest on each one year anniversary of the grant date of the award.
- F5The outstanding principal balance under the convertible note, plus all accrued and unpaid interest thereon, automatically converted into shares of common stock upon the closing of the Issuer's initial public offering at a conversion price equal to 75% of the price at which shares were sold to the public. The convertible note had no expiration date.
- F6Represents a restricted stock award of 28,193 shares of common stock granted under the Issuer's 2014 Equity Incentive Plan. All of the shares subject to the restricted stock award vested immediately upon grant. In order to satisfy certain tax withholding obligations, the Issuer repurchased 11,847 of these shares from the Reporting Person.
- F725% of the shares subject to the option were vested upon grant and 25% of the shares subject to the option will vest on each one year anniversary of the grant date.